Search

Join Us
Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient
A Study of the Natural History of Participants With LGMD2E/​R4, LGMD2D/​R3, LGMD2C/​R5, and LGMD2A/​R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Community Letter: ELEVIDYS Safety Update
A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)
Sarepta Therapeutics Shares Safety Update on ELEVIDYS
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments